| Document |
Document Title |
|
WO/2023/068829A1 |
The present invention relates to a composition comprising iron oxide magnetic particles. The composition can be delivered specifically to hepatocytes to minimize damage to other organs, and is safe as the composition is excreted from the...
|
|
WO/2023/069767A1 |
This present disclosure is directed to methods for detecting and quantifying radioisotopes ( e.g., radiopharmaceuticals) in a liquid and compositions involving the same. Metal-organic frameworks (MOFs) can be synthesized and used for mea...
|
|
WO/2023/065017A1 |
The present description relates to a conjugated compound an antibody covalently linked to enhancer moiety composed by a nuclear localization sequence (NLS), covalently linked to a sterol variant, such as cholic acid (ChAc) or a variant t...
|
|
WO/2023/069711A1 |
Disclosed are compositions for delivering neutron capture agents to cells expressing fibroblast activation protein (FAP), which composition comprises an FAP binding moiety (FAP-bm) associated (covalently or non-covalently) with a neutron...
|
|
WO/2023/069507A1 |
A method for treating a subject having, or at risk of having, damaged endometrial tissue generally includes administering to the subject an amount of a PEP preparation effective to treat the subject's endometrial tissue. The PEP preparat...
|
|
WO/2023/070004A1 |
The present invention provides a compound having the structure (I): and methods of using the compound in targeted PET and SPECT imaging.
|
|
WO/2023/068423A1 |
The present invention relates to: a core/shell-type anticancer composition comprising a core including a photosensitizer represented by chemical formula 1 and a shell including bovine serum albumin or human serum albumin; and a preparati...
|
|
WO/2023/068828A1 |
The present invention relates to a method for preparing a composition comprising iron oxide magnetic particles, and a composition comprising iron oxide magnetic particles, wherein the composition prepared by the preparation method is del...
|
|
WO/2023/066994A1 |
The present invention relates to alginate-based gels for use in radiotherapy. More particularly, the invention provides an alginate gel comprising a peptide-coupled alginate, at least one type of divalent cation, and at least one radionu...
|
|
WO/2023/063154A1 |
[Problem] To provide: a novel tracer drug for radioactive PET diagnosis that has high accumulation properties and retention properties at a tumor site, and an efficient production method (labeling synthesis method) of the tracer drug. [S...
|
|
WO/2023/060317A1 |
The disclosure relates to a radiolabelled conjugate of a trivalent arsenical compound, the use of such a radiolabelled conjugate in the diagnosis and treatment of conditions associated with cell death, such as neoplastic conditions, and ...
|
|
WO/2023/059184A1 |
The invention provides a method for providing a coated nanoparticle material (35), wherein the method comprises (i) a first stage (100), (ii) a second stage (200), and (iii) a coating stage (300), wherein: the first stage (100) comprises...
|
|
WO/2023/056302A1 |
Methods for treating cancers and precancerous conditions by administering an effective amount of a radiolabeled agent that targets cell surface GRP78, alone or in combination with other therapies, are provided. The radiolabeled GRP78 tar...
|
|
WO/2023/049963A1 |
The present invention relates to compounds of formula (I) that have the ability to be used as metal complexes in radiotherapy. Formula (I) wherein A is selected from the group consisting of CO2R1, and PO3R1; B is selected from the group ...
|
|
WO/2023/052816A1 |
Antigen-binding agents such as humanized antibodies or antigen-binding fragments thereof, that specifically bind to epidermal growth factor receptor variant III (EGFRvIII) are provided. The EGFRvIII-specific humanized antibodies or antig...
|
|
WO/2023/056240A2 |
The present invention relates to multispecific molecule complexes. Particularly, this disclosure relates to multispecific protein complexes, such as multispecific antibodies, platform for making different formats of such complexes, and r...
|
|
WO/2023/054285A1 |
The present disclosure relates to: an α-ray emitting antibody-drug conjugate; a method for producing same; a use thereof; a pharmaceutical composition comprising said α-ray emitting antibody-drug conjugate; and a test, diagnosis, and t...
|
|
WO/2023/049985A1 |
Compounds, e.g., radioimmunoconjuguates including a chelating moiety or a metal complex thereof, a linker, and an EGFRvIII targeting moiety. Pharmaceutical compositions of such compounds and methods of treatment for conditions, e.g., can...
|
|
WO/2023/051941A1 |
A radiopeptide is provided which comprises (a) a radionuclide, wherein the radionuclide is terbium-161, (b) a chelator coordinating terbium-161, and (c) a peptide or peptide analogue, which is a somatostatin receptor (SSTR) antagonist. T...
|
|
WO/2023/050008A1 |
Compounds, e.g., radioimmunoconjuguates including a chelating moiety or a metal complex thereof, a linker, and an EGFRvIII targeting moiety. Pharmaceutical compositions of such compounds and methods of treatment for conditions, e.g., can...
|
|
WO/2023/056221A1 |
The disclosure provides multifunctional compounds for use in medical imaging and therapy, the compounds comprising two or more of (i) a chelating ligand moiety (CL); (ii) an optical probe moiety (OP); and (iii) a biological targeting moi...
|
|
WO/2023/044965A1 |
The present invention relates to the technical field of nuclear medicine, and in particular to an SNAP-tag probe, and a preparation method therefor and the use thereof. The SNAP-tag probe has a structure as represented by general formula...
|
|
WO/2023/047357A1 |
The radiopharmaceutical complex for imaging and/or localizing PD-L1 positive cells comprisese at least one anti-PD-L1 monoclonal antibody, wherein the monoclonal antibody is conjugated with at least one beta-emitting radionuclide.
|
|
WO/2023/047319A1 |
The radiopharmaceutical complex for imaging and/or localizing PSMA positive cells, comprises at least one inhibitor of the prostate specific membrane antigen (PSMA), the inhibitor being conjugated to a chelator of at least one alpha-emit...
|
|
WO/2023/047138A1 |
The present invention relates to methods of preparation of a solution comprising an 18F labelled silyl-fluoride compound. Compounds and compositions obtained by the methods of the invention may be useful as positron emission tomography (...
|
|
WO/2023/041524A2 |
The present invention relates to stable and low viscosity liquid pharmaceutical compositions comprising antibodies binding to human alpha synuclein and to methods for use of antibodies binding to human alpha synuclein for treating synucl...
|
|
WO/2023/039415A2 |
Iodide nanoparticles are provided. The nanoparticles can be potassium iodide (KI) nanoparticles, and can be formed of, a radioisotope, preferably 131I or 125I. The nanoparticles can include a coating that can increase the half-life of th...
|
|
WO/2023/037337A1 |
The present invention relates to a pharmaceutical cold kit composition comprising a chelating agent linked to somatostatin receptor binding organic moiety, a stabilizer, a buffer, and a caking agent or bulking agent, wherein the composit...
|
|
WO/2023/038536A1 |
Electrolyte bath, for deposition of nickel coatings, containing Ni2+ cations in an aqueous medium, according to the invention, is characterized by having a pH value in the range of 4.3-4.8, preferably pH = 4.5, and containing Ni2+ cation...
|
|
WO/2023/031934A1 |
A method of treating a neuronal injury in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent that specifically binds to the GAR domain of nucleolin. Methods of treatin...
|
|
WO/2023/031311A1 |
The invention provides new reversible monoacylglycerol lipase (MAGL) inhibitors that are useful for the treatment or prophylaxis of diseases or conditions associated with MAGL. The reversible MAGL inhibitors according to the present inve...
|
|
WO/2023/030509A1 |
A peptide-urea derivative, a pharmaceutical composition containing same and an application thereof are provided, the derivative being as shown in formula I. The derivative can be used for preoperative imaging diagnosis and grading of PSM...
|
|
WO/2023/033049A1 |
Disclosed is an antibody or antibody fragment having binding properties to the mutant SOD1 protein, including: a heavy chain variable region including heavy chain CDR1 composed of an amino acid sequence of GFSLNTSGMG (SEQ ID NO: 1), heav...
|
|
WO/2023/034732A1 |
Disclosed is a compound of Formula (Ib): The compound of Formula (Ib) is useful for positron emission tomography (PET) imaging of Bruton's Tyrosine Kinase (BTK) in mammals. Also disclosed are methods of using the compound as a labeling a...
|
|
WO/2023/030434A1 |
An inhibitor of a prostate specific membrane antigen and a pharmaceutical use thereof. Specifically, the present solution belongs to the field of radiopharmaceuticals and relates to a compound represented by formula (IV) or a pharmaceuti...
|
|
WO/2023/034450A1 |
The present disclosure provides, in part, methods for site-specific labeling of proteins/peptides with radiohalogens and compositions resulting from said methods.
|
|
WO/2023/033022A1 |
The present invention provides "a complex of a chelating agent in which a radionuclide has been chelated and an antibody which has been deglycosylated, wherein the chelating agent site-specifically modifies an Fc region of the antibody v...
|
|
WO/2023/031397A1 |
The invention refers to Fc silenced anti-oxMIF antibodies with improved properties such as reduced aggregation potential and reduced hydrophobicity due to selected amino acid substitutions in the light and heavy chain variable domains, a...
|
|
WO/2023/034810A1 |
Disclosed herein are fusion peptides comprising a fluorescent domain and a rare earth element detection domain capable of binding to a rare earth element and fluorescing when exposed to light when a rare earth element is bound and compos...
|
|
WO/2023/028538A1 |
Provided herein are melanocortin 4 receptor (MC4R) agonist peptides and methods of use thereof for the treatment and/or prevention of eating disorders (e.g., overeating), metabolic disorders (e.g., disorders resulting in positive energy ...
|
|
WO/2023/026236A1 |
Disclosed herein are antibodies or antigen binding fragments thereof that bind prostate specific membrane antigen (PSMA), polynucleotides, vectors, host cells, radioconjugates, antibody drug conjugates and methods of treating cancer usin...
|
|
WO/2023/283627A9 |
The present invention relates to a ligand-SIFA conjugate, comprising, within in a single molecule two separate moieties: (a) one or more ligands which are capable of binding to Fibroblast Activation Protein (FAP), and (b) a silicon-fiuor...
|
|
WO/2023/028613A2 |
Methods for treating cancers and precancerous conditions by administering an effective amount of a radiolabeled agent that targets cell surface phosphatidylserine, alone or in combination with other therapies, are provided. The radiolabe...
|
|
WO/2023/023600A1 |
Provided herein are, inter alia, antibodies, which bind Related-to-Receptor Tyrosine Kinase (Ryk) with high efficiency and specificity. The antibodies and antibody compositions provided herein include, for example, novel light and heavy ...
|
|
WO/2023/023512A1 |
Methods for treating cancers and precancerous conditions by administering an effective amount of a radiolabeled agent that targets cell surface calreticulin, alone or in combination with other therapies, are provided. The radiolabeled ca...
|
|
WO/2023/019308A1 |
The present invention relates to methods for treating diseases and conditions characterised by aberrant cell growth, e.g., cancers, comprising administering a combination of a DNA repair inhibitor and a molecular targeted radioimmunother...
|
|
WO/2023/023261A1 |
Disclosed are compounds useful for imaging cells that overexpress FAP, and for treating cancer. Also disclosed are methods of making said compounds.
|
|
WO/2023/023593A1 |
The present application is related to methods of preparing pharmaceutical compositions comprising a VMAT2 inhibitor and/or identifying therapeutically effective dosages of a VMAT2 inhibitor, wherein the VMAT2 inhibitor is useful for trea...
|
|
WO/2023/019303A1 |
The present invention relates to compounds that can complex a radionuclide and formulations and kits comprising compounds that can complex a radionuclide. The compounds, formulations and kits are of use in radiotherapy and diagnostic ima...
|
|
WO/2023/017101A2 |
A diphosphine precursor compounds of Formula (I), conjugates thereof of Formula (II) and radionuclide conjugate complexes thereof are disclosed herein. The compounds are advantageous at least because they enable the easy one-step extempo...
|
